Imyun Pharma
Modular Protein Conjugates that Redirect Memory T Cells to Kill Targeted Disease Cells
Company Overview
Snapshot
Founded in May 2026 by Leon Boston and Lior Carmon, Imyun Pharma operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing its innovative Immune-Tag Conjugates (ITC™) platform.
Business overview
Imyun Pharma is a biotechnology company specializing in the development of Immune-Tag Conjugates (ITC™), a modular recombinant protein platform designed to leverage existing immune memory for targeted disease cell elimination. The technology utilizes an antibody domain to bind to specific surface markers on pathological cells, delivering a pathogen-derived signal peptide internally. This peptide is then presented on MHC Class I molecules, directing pathogen-primed CD8+ memory T cells to destroy the target cells. The platform is adaptable across various oncology, autoimmune, and inflammatory indications by swapping targeting modules, with its lead preclinical asset, ORION™, currently focused on HER2+ solid tumors. Imyun Pharma operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Biomaterials & Tissue Engineering, targeting the Healthcare & Life Sciences market.
Company Intelligence Q&A
- What is Imyun Pharma's core technology?
- Imyun Pharma's core technology is the Immune-Tag Conjugates (ITC™) platform, which uses modular recombinant proteins to redirect existing immune memory to eliminate targeted disease cells.
- When was Imyun Pharma founded and by whom?
- Imyun Pharma was founded in May 2026 by co-founders Leon Boston and Lior Carmon.
- What is the primary application of Imyun Pharma's lead preclinical asset?
- Imyun Pharma's lead preclinical asset, ORION™, is currently targeting HER2+ solid tumors.
- In which sectors does Imyun Pharma primarily operate?
- Imyun Pharma primarily operates in the Health Tech & Life Sciences sector, with a focus on Pharma & Medical Biotechnology and Biomaterials & Tissue Engineering.
- What is the mechanism of action for Imyun Pharma's ITC™ platform?
- The ITC™ platform uses an antibody domain to bind to a specific surface marker on a pathological cell, delivering a pathogen-derived signal peptide internally. This peptide is then presented on MHC Class I molecules, directing existing pathogen-primed CD8+ memory T cells to destroy the target cell.